© Reuters
–
Pfizer and Moderna have raised prices for their vaccines in their latest contracts with the European Union, taking advantage of continued demand for their products due to the impending possibility of a mandatory third dose, as well as some problems with vector vaccines of their competitors.
This announced The Financial Times was quoted as saying by Reuters, with Pfizer rising by more than 25% and Moderna by more than 10%. Thus, according to parts of the contracts that the publication saw, the new dose prices are respectively 19.50 euros, or 23.15 USD (compared to 15.50 euros before) and 25.50 dollars. For Moderna, this is more than 19 euros ($ 22.60) from the first orders, but lower than the pre-agreed $ 28.50 per dose. The explanation of someone familiar with the treaty is that the numbers that the EU wants have increased.
This is a total of 2.1 billion doses by 2023 for EU citizens and companies have benefited from evidence that vaccines with mRNA technology appear to be more effective. Pfizer has accepted the price agreed for 10 million doses earlier this year for the new contract, but has decided to increase the price of its product anyway when the pandemic ends, according to the FT.
It also proved to be an advantage that orders will be executed in European plants and the risk of delays or delays in deliveries will be significantly reduced, as happened in the spring.
–
